SE460457B - Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa) - Google Patents
Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa)Info
- Publication number
- SE460457B SE460457B SE8103071A SE8103071A SE460457B SE 460457 B SE460457 B SE 460457B SE 8103071 A SE8103071 A SE 8103071A SE 8103071 A SE8103071 A SE 8103071A SE 460457 B SE460457 B SE 460457B
- Authority
- SE
- Sweden
- Prior art keywords
- amsa
- lactic acid
- water
- solid
- solution
- Prior art date
Links
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 title claims description 45
- 239000007787 solid Substances 0.000 title claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- -1 9-ACRIDINYLAMINO Chemical class 0.000 title claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 31
- 229960000448 lactic acid Drugs 0.000 claims description 26
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 22
- 235000014655 lactic acid Nutrition 0.000 claims description 21
- 239000004310 lactic acid Substances 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 10
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 6
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000003708 ampul Substances 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005308 flint glass Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940025708 injectable product Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/147,056 US4360523A (en) | 1980-05-16 | 1980-05-16 | Pharmaceutical formulations of 4'-(9-acridinylamino)-methanesulfon-m-anisidide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8103071L SE8103071L (sv) | 1981-11-17 |
| SE460457B true SE460457B (sv) | 1989-10-16 |
Family
ID=22520148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8103071A SE460457B (sv) | 1980-05-16 | 1981-05-15 | Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US4360523A (en, 2012) |
| JP (1) | JPS579716A (en, 2012) |
| AT (1) | AT374682B (en, 2012) |
| AU (1) | AU543726B2 (en, 2012) |
| BE (1) | BE888832A (en, 2012) |
| CA (1) | CA1160571A (en, 2012) |
| CH (1) | CH647677A5 (en, 2012) |
| DE (1) | DE3119510A1 (en, 2012) |
| DK (1) | DK159376C (en, 2012) |
| FI (1) | FI70793C (en, 2012) |
| FR (1) | FR2482458A1 (en, 2012) |
| GB (1) | GB2076288B (en, 2012) |
| GR (1) | GR75658B (en, 2012) |
| IE (1) | IE51285B1 (en, 2012) |
| IT (1) | IT1170970B (en, 2012) |
| LU (1) | LU83363A1 (en, 2012) |
| NL (1) | NL8102362A (en, 2012) |
| NZ (1) | NZ196985A (en, 2012) |
| SE (1) | SE460457B (en, 2012) |
| YU (1) | YU44831B (en, 2012) |
| ZA (1) | ZA813188B (en, 2012) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575509A (en) * | 1983-01-31 | 1986-03-11 | Bristol-Myers Company | Water-soluble formulations of m-AMSA with pyroglutamic acid |
| US4626541A (en) * | 1985-09-12 | 1986-12-02 | Bristol-Myers Company | Water soluble salt composition of m-AMSA |
| DE3809814C1 (en) * | 1988-03-23 | 1989-09-07 | Karl Heinz Dr.Med. 7100 Heilbronn De Thiel | Use of aminoacridines for iontophoretic treatment of bladder cancer |
| DE3819842C1 (en, 2012) * | 1988-03-23 | 1989-12-21 | Karl Heinz Dr. 7100 Heilbronn De Thiel | |
| CA2143515A1 (en) * | 1994-03-22 | 1995-09-23 | Prakash Parab | Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer |
| DE102004031538A1 (de) * | 2004-06-29 | 2006-02-09 | Baxter International Inc., Deerfield | Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit |
| WO2006002887A1 (en) * | 2004-06-29 | 2006-01-12 | Baxter International Inc. | Aqueous drink solution of indibulin (d-24851) and an organic acid |
| JP2008519036A (ja) * | 2004-11-08 | 2008-06-05 | バクスター・インターナショナル・インコーポレイテッド | チューブリン阻害化合物のナノ粒子組成物 |
| EP2091532A1 (en) * | 2006-11-28 | 2009-08-26 | Ziopharm Oncology, Inc. | Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer |
| US10434077B2 (en) | 2014-03-31 | 2019-10-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Glycolic acid and/or D-lactic acid for the treatment of neurodegenerative diseases |
-
1980
- 1980-05-16 US US06/147,056 patent/US4360523A/en not_active Expired - Lifetime
-
1981
- 1981-04-27 CA CA000376348A patent/CA1160571A/en not_active Expired
- 1981-04-30 YU YU1123/81A patent/YU44831B/xx unknown
- 1981-05-01 NZ NZ196985A patent/NZ196985A/xx unknown
- 1981-05-06 GR GR64859A patent/GR75658B/el unknown
- 1981-05-08 AU AU70291/81A patent/AU543726B2/en not_active Ceased
- 1981-05-13 ZA ZA00813188A patent/ZA813188B/xx unknown
- 1981-05-13 FI FI811474A patent/FI70793C/fi not_active IP Right Cessation
- 1981-05-13 NL NL8102362A patent/NL8102362A/nl not_active Application Discontinuation
- 1981-05-13 FR FR8109497A patent/FR2482458A1/fr active Granted
- 1981-05-14 IT IT48467/81A patent/IT1170970B/it active
- 1981-05-14 DK DK216681A patent/DK159376C/da active
- 1981-05-15 BE BE0/204812A patent/BE888832A/fr not_active IP Right Cessation
- 1981-05-15 IE IE1092/81A patent/IE51285B1/en unknown
- 1981-05-15 CH CH3195/81A patent/CH647677A5/de not_active IP Right Cessation
- 1981-05-15 LU LU83363A patent/LU83363A1/fr unknown
- 1981-05-15 DE DE19813119510 patent/DE3119510A1/de active Granted
- 1981-05-15 GB GB8114947A patent/GB2076288B/en not_active Expired
- 1981-05-15 SE SE8103071A patent/SE460457B/sv not_active IP Right Cessation
- 1981-05-15 JP JP7239381A patent/JPS579716A/ja active Granted
- 1981-05-18 AT AT0221181A patent/AT374682B/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US4360523A (en) | 1982-11-23 |
| GR75658B (en, 2012) | 1984-08-02 |
| DE3119510A1 (de) | 1982-02-25 |
| FI811474L (fi) | 1981-11-17 |
| FR2482458B1 (en, 2012) | 1984-12-14 |
| BE888832A (fr) | 1981-11-16 |
| IE51285B1 (en) | 1986-11-26 |
| YU112381A (en) | 1985-03-20 |
| DK216681A (da) | 1981-11-17 |
| NZ196985A (en) | 1983-06-17 |
| AU7029181A (en) | 1981-11-19 |
| AT374682B (de) | 1984-05-25 |
| YU44831B (en) | 1991-04-30 |
| CH647677A5 (de) | 1985-02-15 |
| SE8103071L (sv) | 1981-11-17 |
| FI70793B (fi) | 1986-07-18 |
| LU83363A1 (fr) | 1982-01-20 |
| ATA221181A (de) | 1983-10-15 |
| IT1170970B (it) | 1987-06-03 |
| JPS579716A (en) | 1982-01-19 |
| FI70793C (fi) | 1986-10-27 |
| CA1160571A (en) | 1984-01-17 |
| FR2482458A1 (fr) | 1981-11-20 |
| IE811092L (en) | 1981-11-16 |
| DK159376B (da) | 1990-10-08 |
| DK159376C (da) | 1991-03-25 |
| GB2076288B (en) | 1983-12-14 |
| AU543726B2 (en) | 1985-05-02 |
| ZA813188B (en) | 1982-05-26 |
| JPH0136445B2 (en, 2012) | 1989-07-31 |
| NL8102362A (nl) | 1981-12-16 |
| IT8148467A0 (it) | 1981-05-14 |
| DE3119510C2 (en, 2012) | 1991-03-07 |
| GB2076288A (en) | 1981-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4890732B2 (ja) | 癌治療用パクリタキセル・リポソーム組成物およびその製造方法 | |
| US20030109514A1 (en) | Platinum derivative pharmaceutical formulations | |
| JPH0354089B2 (en, 2012) | ||
| SE460457B (sv) | Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa) | |
| WO2013071696A1 (zh) | 人体五种正常碱基在制备肿瘤药物中的应用 | |
| JPS604802B2 (ja) | 制癌剤 | |
| ES2280259T3 (es) | Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus. | |
| HUP0202729A2 (hu) | Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények | |
| KR890001236B1 (ko) | 소염제 조성물의 제조방법 | |
| JPH11508566A (ja) | リファブチンを含む抗細菌相乗性組成物 | |
| US4425348A (en) | Antitumor compositions | |
| US4892876A (en) | Method for inhibiting HIV and an pharmaceutical composition therefor | |
| JP2008534521A (ja) | ピリドキサール５’−リン酸の静脈用製剤、調製方法、およびその使用 | |
| JPH0343251B2 (en, 2012) | ||
| US4963588A (en) | Use of ubenimex for treating myelodysplastic syndrome | |
| CN106176626B (zh) | L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物 | |
| JP2003509356A (ja) | リン酸エストラムスチン塩およびスルホアルキルエーテルシクロデキストリンの非経口的使用のための処方 | |
| US4626541A (en) | Water soluble salt composition of m-AMSA | |
| JPH01313433A (ja) | 抗ｈｉｖ剤 | |
| US20250144106A1 (en) | Ready to use non-aqueous solutions of lamotrigine | |
| JP2643340B2 (ja) | ヒト後天性免疫不全症候群ウイルス感染阻害剤 | |
| JP3064027B2 (ja) | 血管新生阻害剤 | |
| JPH0471890B2 (en, 2012) | ||
| RU2333751C1 (ru) | Противовирусное средство | |
| US3517102A (en) | Oxytetracycline antibiotic compositions employing n-(beta-oxyethyl) piperazine or n-n'bis - (beta - oxyethyl) piperazine and magnesium chloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8103071-0 Effective date: 19911209 Format of ref document f/p: F |